Thursday, November 21st – Sala Ulisse, Accademia delle Scienze di Bologna, via Zamboni 31
10.30 Registration
11.30 Welcome address
G. Turchetti (DIFA - UniBo) – Overview and perspectives of compact ICS sources
12.00 K. Achterhold (TUM) – Brilliant Monochromatic X-rays at the Munich Compact Light Source
12.30 K. Dupraz (LAL-Orsay) – The ThomX ICS source
13.00 Quick lunch
14.00 L. Serafini (INFN MI) – MariX/BriXS Design Study
14.30 J. Rosenzweig (UCLA) – Advances in nonlinear inverse Compton scattering physics and technology at UCLA
15.00 L. Labate (INO CNR Pisa) – Laser-driven particle and photon sources for medical applications at ILIL-CNR
15.30 Coffee break
16.00 D. Panetta (CNR-IFC) – PRELUDE: Preclinical tool for advanced translational research with ultra-short and ultra-intense X-ray pulses
16.30 B. Grigoryan (CANDLE SRI ) – AREAL Facility: Status and Plans
17.00 A. Bacci (INFN MI) – The STAR Project
17.30 M. Placidi (LBNL and CERN ret.) – BoCXS: a Compact X-ray Source for the Bologna Metropolitan Area
18.00 Discussion
Friday, November 22nd – Aula Anfitearo, Centro di Ricerca Codivilla Putti, IRCCS Istituto Ortopedico Rizzoli, via di Barbiano 1/10
12.00 Quick lunch
13.00 M. P. Landini (Istituti Rizzoli) – Welcome address
13.10 M. Placidi (LBNL and CERN ret.) – BoCXS: short summary
13.30 B. Günther (TUM) – Medical imaging research and spectroscopy at the MuCLS
14.00 M. Dierolf (TUM) – In vivo X-ray imaging at the MuCLS
14.30 G. Tromba (ELETTRA TRIESTE) – Phase contrast biomedical imaging at the SYRMEP beamline of ELECTRA
15.00 F. Baruffaldi (Istituti Rizzoli) – X-ray imaging of the skeleton: a review of clinical and research applications
15.30 Coffee break
16.00 M. Bertolini (IRCCS Reggio Emilia) – X-ray medical imaging at Azienda USL-IRCCS Reggio Emila
16.30 A. Taibi (UniFe) – Potential applications of ICS in Biomedical imaging
17.00 R. Calandrino (IRCCS San Raffaele, Milano) – State of art and optimization perspectives for breast imaging
17.30 Round Table discussion and summary
18.30 G. Turchetti (DIFA - UniBo) – Closing remarks
